Astrid Maria Thomas

Curriculum Vitae

Main research:

Out clinic research in Movement disorders like Parkinson’s Disease, young onset Parkinson’s Disiease, atypical parkinsonism  neurodegenerative Diseases (Alzheimer, PPA, PSP, LBD, CGBD etc.)

-      trainer for Pharamstar  and UBC –  ADAS-cog , ADL, CDR UPDRS, MMSE, NMSS, Moca

-      trainer/national language expert (German and Italian ) for Bracket now Signant Health in PD and AD  experimental trails since 2015-present

-      my teaching experience is with students/residencies at the University, Residency, post doctoral research groups and Neurologist  The main topics are EEG and evoked potentials: technique and clinical applications,  degenerative diseases as Parkinson’s Disease, Alzheimer Disease, PPA, PSP, LBD, CBD , cognitive evaluation with specific tests.

-      I am member of the Ethical Committee of the Pescara and Chieti Italy since 2010 ongoing

Since 1993 Investigator in phase II,III, IV international drug research:  The drugs tested were:

Amisulpride, Apomorfina, Botox, babinazumab Cabergolina, CHF 1512, Citidina, Donepezil, Duodopa, Entacapone, E2007, Felbamate, FP0011, FP0153, Galantamine, Impax, Istradefilina, Lamotrigina, Levitiracetam, Lisuride, L-Threo-Dops, Melperone, memantine, Nicergolina, Paroxetine, Paradupronox, Parampanel, Pergolide, Pramipexole, PXl 110253, Ralfinamide, Rasagelina, Rivastigmina, Ropinirole, Rosiglitazone, Rotigotina, Safinamide, Sarizotan, SCH 420814, SLV308, solinazumab Stalevo, Tau-Rx,  TCH 346, Tolcapone, Topimarato,  CTH-201, Neuroderm,  several Bace inhibitors for Merk, Novartis Esai, Tozadenant, IPH11004, KW 6002, PXT-CL17, Preladenant, Neuroderm, apofin sublingual,

*        Consultant for drug companies : Newron,  Neuroderm, Zambon , Novartis,

 

Consulent EMA ongoing

*       in 2017 I have been involved qualification opinion by EMA ; EMA /765041/2017

*       in 2018     SAG Neurology meeting on Namuscla on 6 July in London Ema